WO2004034061A3 - Method for determining the susceptibility of a subject to infection - Google Patents

Method for determining the susceptibility of a subject to infection Download PDF

Info

Publication number
WO2004034061A3
WO2004034061A3 PCT/EP2003/011240 EP0311240W WO2004034061A3 WO 2004034061 A3 WO2004034061 A3 WO 2004034061A3 EP 0311240 W EP0311240 W EP 0311240W WO 2004034061 A3 WO2004034061 A3 WO 2004034061A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
subject
susceptibility
determining
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/011240
Other languages
French (fr)
Other versions
WO2004034061A2 (en
Inventor
Hans Boman
Mats Andersson
Katrin Puetsep
Goeran Carlsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mabtech AB
Original Assignee
Mabtech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabtech AB filed Critical Mabtech AB
Priority to US10/530,606 priority Critical patent/US7591997B2/en
Priority to EP03773640A priority patent/EP1549957B1/en
Priority to DE60332257T priority patent/DE60332257D1/en
Priority to AU2003282027A priority patent/AU2003282027B2/en
Priority to CA002501926A priority patent/CA2501926A1/en
Priority to AT03773640T priority patent/ATE465411T1/en
Priority to JP2004542487A priority patent/JP4874545B2/en
Publication of WO2004034061A2 publication Critical patent/WO2004034061A2/en
Publication of WO2004034061A3 publication Critical patent/WO2004034061A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to diagnosis of neutropenia and to methods for determining susceptibility to infection. The invention also relates to methods for treating neutropenia and treating and/or preventing infections. The inventors have shown that a reduction in the levels of LL-37 in the saliva and neutrophils results in an increased susceptibility to periodontal infections caused mainly by bacteria from the normal oral flora. The present invention provides a method for determining the susceptibility of a subject to infection, which method comprises: i) providing a sample from said subject; ii) detecting any LL-37 present in said sample; iii) optionally comparing the level of LL-37 in said sample to a control. sample; and iv) determining the susceptibility of said subject to infection, wherein no LL-37 or a low level of LL-37 indicates that said subject is susceptible to infection.
PCT/EP2003/011240 2002-10-10 2003-10-10 Method for determining the susceptibility of a subject to infection Ceased WO2004034061A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/530,606 US7591997B2 (en) 2002-10-10 2003-10-10 Method for determining the susceptibility of a subject to infection
EP03773640A EP1549957B1 (en) 2002-10-10 2003-10-10 Method for determining the susceptibility of a subject to infection
DE60332257T DE60332257D1 (en) 2002-10-10 2003-10-10 METHOD FOR DETERMINING THE NERVATION OF A PERSON FOR INFECTION
AU2003282027A AU2003282027B2 (en) 2002-10-10 2003-10-10 Method for determining the susceptibility of a subject to infection
CA002501926A CA2501926A1 (en) 2002-10-10 2003-10-10 A method for determining the susceptibility of a subject to oral infection by the detection of ll-37
AT03773640T ATE465411T1 (en) 2002-10-10 2003-10-10 METHOD FOR DETERMINING A PERSON'S SUSPENSION TO INFECTION
JP2004542487A JP4874545B2 (en) 2002-10-10 2003-10-10 Method for determining a subject's susceptibility to oral infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0223655.2 2002-10-10
GBGB0223655.2A GB0223655D0 (en) 2002-10-10 2002-10-10 Method of diagnosis

Publications (2)

Publication Number Publication Date
WO2004034061A2 WO2004034061A2 (en) 2004-04-22
WO2004034061A3 true WO2004034061A3 (en) 2004-05-21

Family

ID=9945734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011240 Ceased WO2004034061A2 (en) 2002-10-10 2003-10-10 Method for determining the susceptibility of a subject to infection

Country Status (9)

Country Link
US (1) US7591997B2 (en)
EP (1) EP1549957B1 (en)
JP (1) JP4874545B2 (en)
AT (1) ATE465411T1 (en)
AU (1) AU2003282027B2 (en)
CA (1) CA2501926A1 (en)
DE (1) DE60332257D1 (en)
GB (1) GB0223655D0 (en)
WO (1) WO2004034061A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0300207D0 (en) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
JP2010539057A (en) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Use of human pancreatic polypeptides as therapeutic agents
RU2010114049A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) CGRP AS A THERAPEUTIC
US20190300575A1 (en) * 2018-03-29 2019-10-03 Deetex, LLC Lytic peptide biosensor and methods of making and using the same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011663A1 (en) * 1997-08-29 1999-03-11 Genset HUMAN DEFENSIN DEF-X, GENE AND DNAc, COMPOSITION CONTAINING SAME AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
WO1999013080A1 (en) * 1997-09-10 1999-03-18 Zymogenetics, Inc. Beta-defensins
US5972594A (en) * 1997-02-05 1999-10-26 University Of Pittsburgh Method for screening for reproductive tract inflammation and preeclampsia using neutrophil defensins
US6159936A (en) * 1993-07-20 2000-12-12 The Regents Of The University Of California Compositions and methods for treating and preventing microbial and viral infections
JP2001288105A (en) * 2000-04-05 2001-10-16 Yoshihiro Abiko Medicine for periodontitis
DE10028725A1 (en) * 2000-06-09 2001-12-13 Juergen Bux Primary structure and nucleic acid of the human neutrophil antigen-2a, useful for antigen detection, e.g. diagnosis of various forms of neutropenia
WO2002060468A2 (en) * 2001-01-30 2002-08-08 University Of Iowa Research Foundation Antiviral activities of primate theta defensins and mammalian cathelicidins
US20030175755A1 (en) * 2002-03-05 2003-09-18 Yoshihiro Abiko Method of collecting data for estimation of susceptibility to periodontal disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301797A2 (en) * 2000-07-17 2003-04-16 Hansa Medical AB Antimicrobial agent
AU2001289813B2 (en) * 2000-08-17 2005-07-28 Intercell Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159936A (en) * 1993-07-20 2000-12-12 The Regents Of The University Of California Compositions and methods for treating and preventing microbial and viral infections
US5972594A (en) * 1997-02-05 1999-10-26 University Of Pittsburgh Method for screening for reproductive tract inflammation and preeclampsia using neutrophil defensins
WO1999011663A1 (en) * 1997-08-29 1999-03-11 Genset HUMAN DEFENSIN DEF-X, GENE AND DNAc, COMPOSITION CONTAINING SAME AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
WO1999013080A1 (en) * 1997-09-10 1999-03-18 Zymogenetics, Inc. Beta-defensins
JP2001288105A (en) * 2000-04-05 2001-10-16 Yoshihiro Abiko Medicine for periodontitis
DE10028725A1 (en) * 2000-06-09 2001-12-13 Juergen Bux Primary structure and nucleic acid of the human neutrophil antigen-2a, useful for antigen detection, e.g. diagnosis of various forms of neutropenia
WO2002060468A2 (en) * 2001-01-30 2002-08-08 University Of Iowa Research Foundation Antiviral activities of primate theta defensins and mammalian cathelicidins
US20030175755A1 (en) * 2002-03-05 2003-09-18 Yoshihiro Abiko Method of collecting data for estimation of susceptibility to periodontal disease

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GOMBART ADRIAN F ET AL: "Neutrophil-specific granule deficiency: Homozygous recessive inheritance of a frameshift mutation in the gene encoding transcription factor CCAAT/enhancer binding protein-epsilon", BLOOD, vol. 97, no. 9, 1 May 2001 (2001-05-01), pages 2561 - 2567, XP002275342, ISSN: 0006-4971 *
JUREVIC R J ET AL: "Single-nucleotide polymorphisms and haplotype analysis in [beta]-defensin genes in different ethnic populations", GENETIC TESTING 2002 UNITED STATES, vol. 6, no. 4, 2002, pages 261 - 269, XP002969563, ISSN: 1090-6576 *
LEHRER ROBERT I ET AL: "Cathelicidins: a family of endogenous antimicrobial peptides.", CURRENT OPINION IN HEMATOLOGY. UNITED STATES JAN 2002, vol. 9, no. 1, January 2002 (2002-01-01), pages 18 - 22, XP008028914, ISSN: 1065-6251 *
LEVY OFER: "Antimicrobial proteins and peptides of blood: Templates for novel antimicrobial agents", BLOOD, vol. 96, no. 8, 15 October 2000 (2000-10-15), pages 2664 - 2672, XP002224605, ISSN: 0006-4971 *
NIZET V ET AL: "Innate antimicrobial peptide protects the skin from invasive bacterial infection", NATURE 22 NOV 2001 UNITED KINGDOM, vol. 414, no. 6862, 22 November 2001 (2001-11-22), pages 454 - 457, XP002275343, ISSN: 0028-0836 *
ONG PECK Y ET AL: "Endogenous antimicrobial peptides and skin infections in atopic dermatitis", NEW ENGLAND JOURNAL OF MEDICINE, vol. 347, no. 15, 10 October 2002 (2002-10-10), pages 1151 - 1160, XP008028910, ISSN: 0028-4793 *
PUTSEP KATRIN ET AL: "Deficiency of antibacterial peptides in patients with morbus Kostmann: An observation study", LANCET (NORTH AMERICAN EDITION), vol. 360, no. 9340, 12 October 2002 (2002-10-12), pages 1144 - 1149, XP002275344, ISSN: 0099-5355 *
WEINBERG A ET AL: "Epithelial antimicrobial peptides: Review and significance for oral applications", CRITICAL REVIEWS IN ORAL BIOLOGY AND MEDICINE, vol. 9, no. 4, November 1998 (1998-11-01), pages 399 - 414, XP000972953, ISSN: 1045-4411 *
ZETTERSTRÖM ROLF: "Kostmann disease--infantile genetic agranulocytosis: historical views and new aspects.", ACTA PAEDIATRICA (OSLO, NORWAY: 1992) NORWAY 2002, vol. 91, no. 12, 2002, pages 1279 - 1281, XP008028913, ISSN: 0803-5253 *

Also Published As

Publication number Publication date
EP1549957B1 (en) 2010-04-21
US20070059691A1 (en) 2007-03-15
DE60332257D1 (en) 2010-06-02
ATE465411T1 (en) 2010-05-15
AU2003282027B2 (en) 2010-05-13
JP4874545B2 (en) 2012-02-15
US7591997B2 (en) 2009-09-22
AU2003282027A1 (en) 2004-05-04
CA2501926A1 (en) 2004-04-22
WO2004034061A2 (en) 2004-04-22
GB0223655D0 (en) 2002-11-20
JP2006502395A (en) 2006-01-19
EP1549957A2 (en) 2005-07-06

Similar Documents

Publication Publication Date Title
Quirynen et al. Dynamics of initial subgingival colonization of ‘pristine’peri‐implant pockets
ZA200409291B (en) Compositions and methods for coating medical implants
WO2004027020A3 (en) Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
EP1718334A4 (en) METHODS OF DIAGNOSING AND TREATING PREECLAMPSIA OR ECLAMPSIA
WO2004042346A3 (en) Methods and compositions for diagnosing and monitoring transplant rejection
WO2005029067A3 (en) Method of diagnosing breast cancer
WO2004031410A3 (en) Method for diagnosing testicular seminomas
EP2368569A3 (en) Compositions and methods related to staphylococcal bacterium proteins
AU2003233451A1 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
WO2005028665A3 (en) Campylobacter polypeptides and methods of use
WO2007068985A3 (en) Diagnosis and prognosis of colorectal cancer
WO2002068679A3 (en) Determining the risk of caries in a patient
WO2002088425A3 (en) Determination of chloride corrosion threshold for metals embedded in cementitious material
PT932613E (en) EXPRESSION OF BLOCKING VIRULENCE FACTS IN S. AUREUS
WO2001091461A3 (en) Watermark detection
WO2005001141A3 (en) Methods and nucleic acids for analyses of colorectal cell proliferative disorders
PL378054A1 (en) Method for detecting escherichia coli
AU2003262090A1 (en) Method for reduction treatment of metal oxide or ironmaking waste, and method for concentration and/or recovery of zinc and/or lead
SE0401631L (en) New composition
WO2006065273A3 (en) New human parvovirus
WO2005111080A3 (en) Methods for reducing biofilm formation in infectious bacteria
Kitano et al. Suppression of gingival inflammation induced by Porphyromonas gingivalis in rats by leupeptin
GB0223655D0 (en) Method of diagnosis
BRPI0408067A (en) autism diagnosis
WO2004029216A3 (en) Diagnosis of invasive mold infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2501926

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004542487

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003282027

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003773640

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003773640

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007059691

Country of ref document: US

Ref document number: 10530606

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10530606

Country of ref document: US